San Diego, CA (PRWEB) June 25, 2015 -- BPS Bioscience, Inc. (“BPS”) announces the expansion of its panel of Histone Demethylase (“HDM”) enzymes for screening and profiling of potential inhibitors. BPS Bioscience’s unique panel now includes 17 different HDM isozymes.
Demethylases are enzymes that remove methyl groups from lysine and arginine residues of proteins, the most commonly studied being histone demethylases. Methylation of histones is essential for regulating transcription and maintaining chromatin structure. Demethylases, like all histone modifying enzymes, play an important role in development and gene regulation. All of the demethylases identified to date, with the exception of LSD1, contain a catalytic jumonji domain.
Like methyltransferases, demethylases exhibit a high level of substrate specificity with respect to their target lysine or arginine. In addition, they are sensitive to the specific type of methylation that they recognize and subsequently demethylate. For example, some demethylases are only capable of demethylating mono- or dimethyl substrates, whereas others are capable of demethylating all states of methylation.
Given the critical role that demethylases play in gene regulation, it is not surprising that they have been linked to many human cancers. BPS was the first company to supply active, high purity histone demethylases for life science research. BPS provides a unique and comprehensive offering of enzymes, assay kits, and inhibitors/activators to meet all of your research needs. This large portfolio of substrates, which includes a number of modified histones, makes it easy to study histone demethylase substrate specificity.
“BPS has been providing first class screening and profiling services to pharmaceutical and academic research communities since 2007. These novel demethylase assays will enable our customers to assay an even wider range of demethylase isoforms,” said Henry Zhu, President and CEO, BPS Biosciences, Inc. "BPS continues to expand its portfolio to help researchers move lead compounds through their development pipelines and into the clinic.”
In addition to expanding the services portfolio, BPS provides the largest commercially available selection of demethylase enzymes, assay kits, substrates, inhibitors, and other tools for epigenetic research. The expansion of BPS’ HDM screening and profiling services complement the broad array of drug discovery tools and world class custom biochemical services already offered by BPS.
To learn more about BPS Bioscience’s HDM services please visit http://bpsbioscience.com/screening-profiling-services/histone-demethylase-screening-profiling-services, and to learn more about all of the HDM products BPS offers please visit http://bpsbioscience.com/demethylase.
About BPS Bioscience, Inc.
Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Methyltransferases, Kinases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases (PARPs), Proteases, Ubiquitin Enzymes, Methyl-lysine Readers and other Metabolic Enzymes. BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: http://www.bpsbioscience.com.
Henry Zhu, BPS Bioscience, http://www.bpsbioscience.com, +1 (858) 829-3082, [email protected]